Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
about
Plasmodium vivax DBP binding to Aotus nancymaae erythrocytes is Duffy antigen dependentPlasmodium malaria and antimalarial antibodies in the first year of lifeProduction of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line systemPredicting in vivo anti-hepatofibrotic drug efficacy based on in vitro high-content analysisImmunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1A Method for Producing Protein Nanoparticles with Applications in VaccinesT cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccinesSafety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaquesPhase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adultsRecombinant Plasmodium falciparum reticulocyte homology protein 4 binds to erythrocytes and blocks invasionPhase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malariaProtection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens.Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responsesAcquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum.Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adultsCross-species malaria immunity induced by chemically attenuated parasites.In vitro growth-inhibitory activity and malaria risk in a cohort study in maliPlasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.The Plasmodium falciparum merozoite surface protein-1 19 KD antibody response in the Peruvian Amazon predominantly targets the non-allele specific, shared sites of this antigen.Strategies for designing and monitoring malaria vaccines targeting diverse antigensImpact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.Transplacentally transferred functional antibodies against Plasmodium falciparum decrease with age.Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development.Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans.Advances and challenges in malaria vaccine development.Non-variant specific antibody responses to the C-terminal region of merozoite surface protein-1 of Plasmodium falciparum (PfMSP-1(19)) in Iranians exposed to unstable malaria transmission.Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys.Antibody and T cell responses in reciprocal prime-boost studies with full-length and truncated merozoite surface protein 1-42 vaccines.Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodiesPlasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies.Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine designConjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidatesStructural basis of antigenic escape of a malaria vaccine candidatePlasmodium falciparum line-dependent association of in vitro growth-inhibitory activity and risk of malaria.Polymorphism and epitope sharing between the alleles of merozoite surface protein-1 of Plasmodium falciparum among Indian isolates.Antibodies to Plasmodium falciparum merozoite surface protein-1p19 malaria vaccine candidate induce antibody-dependent respiratory burst in human neutrophilsEnhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens.Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?
P2860
Q24596355-8C0D0347-8E5C-4AFB-ACE2-5F7C65F02A65Q26315542-C9D8F8C9-E30C-4306-829C-E90C5A8E4C0AQ26700012-D063AF13-1762-42CF-B7DD-3808B3BC141FQ28477748-524A0A8F-0B92-4FDB-9F51-D058AF6F991FQ28484081-421E1C3B-C56E-48B9-AEA7-41520FD8294AQ28550575-5A2CFB9D-BE4E-4089-9D26-0360AB6356E2Q28740432-0B625EE1-E1C4-441F-9FF1-4D239C6A4C15Q28742239-0747F4E3-BD0F-49C9-863B-874E4D884576Q28749215-4CA0D65B-A000-4E7C-9E11-D96C2F1EEFABQ30043667-7B4B6B0A-4431-4C02-A7A9-8562F55C0832Q33281394-018446CC-E500-408A-AA4E-8F101D032947Q33303670-A4DA98D5-5146-44F6-AAAE-2444A0DAE439Q33356029-1BF45D46-E66F-4F37-846C-521DCC1BD8F2Q33380204-B4B0D252-3D43-4B06-80AB-0FE805229DFEQ33380213-86752101-B7EC-4919-B769-47686D565DCBQ33570804-14FC9558-5D38-4126-B81E-3B45334C6E1DQ33613892-8E197363-5FF9-44F2-8D61-4EE423AF2559Q33613937-EE7D7CD4-26FC-4949-9E53-55ED09603EFDQ33638725-81A6970A-6255-4127-A31D-8441540CC02DQ33959038-132A178B-5580-4811-857E-5957019B1903Q33974904-DF664521-64AC-4B0A-A9AB-833A93BB9522Q34060022-55DB0078-5EC3-4875-820F-8F72D5D706A7Q34069682-9BBD3520-ADFF-4D5A-A7C1-C2F7187181B4Q34081745-27B8B055-0E49-46C6-8EFD-972D77793342Q34145333-0FAC5769-A954-4829-B82D-910536EB10D1Q34154429-DAD3C773-4EA8-4BF5-A2B4-6A793414DF18Q34441098-2E516842-11C5-4EA6-A15A-6C919ACE75DFQ34978590-C382E239-8688-4165-81B0-B0EB3E12963AQ35010158-83F10C5C-C12B-4AC8-A211-3FA1A3F5A025Q35456892-4FD19B24-10BD-487A-AC30-3745E77DABBFQ35762375-52AF0F7D-1818-4CE8-9723-55FA0F314259Q35841913-69621752-92A5-4FF2-9A7F-F2408EA0A26FQ35887367-F0634AF1-ED08-42C8-B129-C40CD09569B1Q35925379-0E8D8130-FE77-4C49-90E8-8E2313941A2CQ35927982-AE9CCDE7-9A1E-43C1-B78B-C8B9ED3ADD2DQ35944117-5BC4BB93-045E-4E07-B2DB-455426CF5883Q35945359-4AE62FE0-4DF9-49DC-AD7D-44B52A766BBEQ36169093-8A59806C-0D66-464E-A00F-3C0C44AF16EAQ36384456-0263711B-A6C2-4E33-AEBA-84C66AC5C1A2Q36391845-54AEB658-7E31-4B79-B963-E14C27A6D4B3
P2860
Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Immunity to recombinant plasmo ...... parasite-inhibitory activity.
@ast
Immunity to recombinant plasmo ...... parasite-inhibitory activity.
@en
Immunity to recombinant plasmodium falciparum merozoite surface protein 1
@nl
type
label
Immunity to recombinant plasmo ...... parasite-inhibitory activity.
@ast
Immunity to recombinant plasmo ...... parasite-inhibitory activity.
@en
Immunity to recombinant plasmodium falciparum merozoite surface protein 1
@nl
prefLabel
Immunity to recombinant plasmo ...... parasite-inhibitory activity.
@ast
Immunity to recombinant plasmo ...... parasite-inhibitory activity.
@en
Immunity to recombinant plasmodium falciparum merozoite surface protein 1
@nl
P2093
P2860
P50
P356
P1476
Immunity to recombinant plasmo ...... parasite-inhibitory activity.
@en
P2093
Aaron Miles
Allan J Saul
Brian Keegan
Laura B Martin
Olga Muratova
Sanjay Singh
P2860
P304
P356
10.1128/IAI.01679-05
P407
P577
2006-08-01T00:00:00Z